TITLE

Gene Therapy for Heart Failure: Back to the Bench

AUTHOR(S)
Ylä-Herttuala, Seppo
PUB. DATE
October 2015
SOURCE
Molecular Therapy;Oct2015, Vol. 23 Issue 10, p1551
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The author reflects on the use of gene therapy for the treatment of heart failure. He mentions pharmaceutical firm Celladon Corp. which announced that its Mydicar adeno-associated viral vector 1 (AAV1)-expressing sarcoplasmic reticulum calcium ATPase drug for heart failure has failed in the second phase of the clinical trial. Also discussed are the factors that contributed to Celladon's failure and the need for developing efficient targeted vectors and delivery methods for heart failure.
ACCESSION #
110162822

 

Related Articles

  • Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1—SERCA2a gene delivery in experimental heart failure. Mariani, Justin A.; Smolic, Anka; Preovolos, Arthur; Byrne, Melissa J.; Power, John M.; Kaye, David M. // European Journal of Heart Failure;Mar2011, Vol. 13 Issue 3, p247 

    Aims Down-regulation of sarcoplasmic reticulum calcium ATPase (SERCA2a) is a key molecular abnormality in heart failure (HF), which is not currently addressed by specific pharmacotherapy. We sought to evaluate, in detail, the impact of augmented SERCA2a expression on left ventricular (LV)...

  • PHASE 2 SHOWS IMPROVEMENT WITH MYDICAR FOR HEART FAILURE.  // Worldwide Biotech;Jul2010, Vol. 22 Issue 7, p1 

    The article deals with the results reported by Celladon Corp. in July 2010 from its Phase 2 clinical trial of Mydicar, a genetically targeted enzyme replacement therapy. Accordingly, the findings demonstrated the primary safety and efficacy endpoints for high dose Mydicar against placebo. Noted...

  • More Hands on Molecular Deck Key to Heart Failure Treatment. Breindl, Anette // BioWorld Today;3/18/2011, Vol. 22 Issue 53, p1 

    The article reports that omecamtiv mecarbil, the lead compound of Cytokinetics Inc., is in Phase II trials for heart failure treatment. According to researchers, the drug improves the heart's pumping ability by activating myosin. The drug also facilitates the use of adenosine 5'-triphosphate...

  • Clinic Roundup.  // BioWorld Today;5/24/2011, Vol. 22 Issue 100, p3 

    This section offers news briefs on several issues involving clinical trials. Anavex Life Sciences Corp. announced that the safety review committee for the Phase I trial of ANAVEX 2-73 approved skipping the dosage received by the volunteers to the 10 milligram (mg) dose cohort. Celladon Corp....

  • Clinic Roundup.  // BioWorld Today;9/27/2013, Vol. 24 Issue 186, p7 

    This section offers clinical news briefs on the biotechnology and pharmaceutical industries. Celladon Corp. has released results from the Phase IIa of its CUPID 1 trial of the drug Mydicar for the treatment of advanced heart failure. The publication "New England Journal of Medicine" has...

  • Percutaneous methods of vector delivery in preclinical models. Ladage, D; Ishikawa, K; Tilemann, L; Müller-Ehmsen, J; Kawase, Y // Gene Therapy;Jun2012, Vol. 19 Issue 6, p637 

    Cardiovascular disease remains a leading cause of hospitalization and mortality worldwide. Conventional heart failure treatment is making steady and substantial progress to reduce the burden of disease. Nevertheless novel therapies and especially cardiac gene therapy have been emerging in the...

  • New trials put heart into gene therapy. Cohen, Philip // New Scientist;7/27/2002, Vol. 175 Issue 2353, p15 

    Examines the usability of gene therapy in the treatment of heart failure in San Diego, California. Causes of heart failure; Importance of phospholamban on regulating heart muscle activity; Side-effects of gene therapy.

  • New trials of gene therapy for heart failure start recruiting patients. Watts, Geoff // BMJ: British Medical Journal;5/4/2013, Vol. 346 Issue 7906, p1 

    The article reports on the launch of gene therapy trials from the British Heart Foundation including CUPID2 and SERCA- left ventricular assist device (LVAD) for the treatment of heart failure in Great Britain.

  • Cardiovascular disease: Powering up a failing heart. Man Tsuey Tse // Nature Reviews Drug Discovery;May2011, Vol. 10 Issue 5, p338 

    The article discusses the cardiac myosin activation. It references the article "Cardiac myosin activation: a potential therapeutic approach for systolic heart failure" by F. I. Malik and colleagues in the 2011 issue of "Science." It highlights that the cardiac myosin activation can be done...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics